Aetna has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors)
Inflammation & Injury Recovery Research has consistently pointed to BPC-157s ability to reduce inflammation at injury sites in a targeted way supporting the bodys natural healing processes rather than simply suppressing the immune response
J Pharmacol Sci 95:1926 Prkacin I, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Staresinic M, Anic T, Mikus D et al (2001) Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine
Lost 65lbs
Unless and until large, well-designed human trials clarify safety and efficacy, BPC-157 remains an unapproved peptide, subject to regulatory controls and compliance requirements in drug-tested populations
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone F M Ng 1, J Sun, L Sharma, R Libinaka, W J Jiang, R Gianello Affiliations expand PMID: 11146367 DOI: 10.1159/000053183 All articles and product information on this website are for educational purposes only
.png.jpg)
